EVAX Quote, Financials, Valuation and Earnings

Ascendis Pharma AS has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -22.12%. Evaxion Biotech AS's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand Ascendis Pharma AS has an analysts' consensus of $211.37 which suggests that it could grow by 25.19%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.413%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Ascendis Pharma AS quarterly revenues of $185.4M. Evaxion Biotech AS's net income of -$1.9M is higher than Ascendis Pharma AS's net income of -$41M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus 24.94x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -142.32%. Evaxion Biotech AS's return on equity of -- beat Cellectis SA's return on equity of -79.78%.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 367.74%. Given that Evaxion Biotech AS has higher upside potential than Cellectis SA, analysts believe Evaxion Biotech AS is more attractive than Cellectis SA.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.275, suggesting its more volatile than the S&P 500 by 227.454%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Cellectis SA quarterly revenues of $16.2M. Evaxion Biotech AS's net income of -$1.9M is higher than Cellectis SA's net income of -$23.1M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus 3.82x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of --. Evaxion Biotech AS's return on equity of -- beat DBV Technologies SA's return on equity of --.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 347.91%. Given that Evaxion Biotech AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion Biotech AS is more attractive than DBV Technologies SA.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion Biotech AS's net income of -$1.9M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of 32.95%. Evaxion Biotech AS's return on equity of -- beat Novo Nordisk AS's return on equity of 86.85%.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand Novo Nordisk AS has an analysts' consensus of $112.90 which suggests that it could grow by 48.19%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.88% to investors and pays a quarterly dividend of $0.52 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Evaxion Biotech AS's net income of -$1.9M is lower than Novo Nordisk AS's net income of $4B. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus 8.18x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.